Elbasvir/grazoprevir
Two drug combination for the treatment of hepatitis C / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Zepatier?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Elbasvir/grazoprevir, sold under the brand name Zepatier, is a fixed-dose combination for the treatment of hepatitis C, containing elbasvir (an inhibitor of hepatitis C virus's NS5A protein) and grazoprevir (an NS3/4A inhibitor). It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and treatment-experienced patients.[3]
Quick Facts Combination of, Grazoprevir ...
Combination of | |
---|---|
Elbasvir | NS5A inhibitor |
Grazoprevir | NS3/4A protease inhibitor |
Clinical data | |
Trade names | Zepatier |
AHFS/Drugs.com | zepatier |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
KEGG |
Close
Both elbasvir and grazoprevir were developed by Merck & Co. The US Food and Drug Administration (FDA) approved the drug in January 2016.[5]